End stage renal disease. End stage kidney disease
Conditions
Interventions
Intervention 1: Intervention group: N-acetylcysteine tab, 600 mg bid for 1 month period. Intervention 2: Control group: placebo tab bid, for 1 month period.
Treatment - Drugs
Intervention group: N-acetylcysteine tab, 600 mg bid for 1 month period
Control group: placebo tab bid, for 1 month period
Sponsors
Vice Chancellor for research of Ardabil University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with positive CRP who were dialyzed at least three times per week for three months Exclusion criteria: Patients with chronic inflammatory diseases such as rheumatoid arthritis and lupus, patients who take HRT drugs during menopause ,patients with malignant blood diseases such as myelodysplastic syndrome, lymphoma, leukemia, bone marrow aplasia and patients with HIV
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CRP. Timepoint: Before the intervention and one month after intervention. Method of measurement: ELIZA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin. Timepoint: Before the intervention and one month after intervention. Method of measurement: CBC. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoya Alaei
Ardabil University of Medical Sciences
Outcome results
None listed